Table 2 Participant characteristics in models 2 and 3

Characteristics	Total (N = 1402)	Model 2							Model 3
	Total (N = 1402)	Discovery set (N = 295)			Validation set (N = 1107)				Discovery set (N = 223)			Validation set (N = 320)
	N	N	Mean	SD	N	Mean	SD	p	N	Mean	SD	N	Mean	SD	p
Ovarian carcinoma	333	160			160				160			173
Age, years			56.8	11.5		57.1	11.6	0.79^a		56.8	11.5		57.1	11.6	0.79^a
Histopathological subtypes								0.29^b							0.29^b
Serous	182	90			92				90			92
Clear cell	64	37			27				37			27
Endometrioid	43	17			26				17			26
Mucinous	14	6			8				6			8
Other carcinoma	17	10			7				10			7
Non-epithelial cancer	13				13							13
Stage								0.97^b							0.97^b
I	82	39			43				339			43
II	33	15			18				15			18
III–IV	218	106			112				104			112
Other cancers	859	120			739
BC	115	15			100
CC	115	15			100
ESCC	88	15			73
GC	115	15			100
HC	81	15			66
LC	115	15			100
PDA	115	15			100
SA	115	15			100
Borderline ovarian tumor	66				66				33			33
Age, years						53	15.5			51.6	15.3		54.3	15.9	0.50^a
Histopathological subtypes															0.85^b
Serous					18				10			8
Mucinous					32				17			15
Granulosa cell					5				2			3
Others					11				4			7
Stage															0.51^b
I					56				26			30
II					5				3			2
III					5				4			1
Benign ovarian tumor	29				29				15			14
Age, years						57.2	10.3			52.2	7.6		62.6	10.3	0.004^a
Histopathological subtypes															0.73^b
Serous					5				2			3
Mucinous					11				7			4
Others					13				6			7
Non-cancer controls	115	15			100				15			100
Age, years			45.5	10.8		45.6	9	0.97^a		45.5	10.8		45.6	9	0.97^a

BC breast carcinoma, CC colorectal adenocarcinoma, ESCC esophageal squamous cell carcinoma, GC gastric adenocarcinoma, HC hepatocellular carcinoma, LC lung carcinoma, PDA pancreatic ductal adenocarcinoma, SA bone and soft tissue sarcoma
^aStudent’s t-test
^bχ² test

Quick links

Search